Folate-modified, cisplatin-loaded lipid carriers for cervical cancer chemotherapy

References

• Andey T, Sudhakar G, Marepally S, et al. (2015). Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation. Mol Pharm 12:1105–20
   PubMed Web of Science ®Google Scholar
• Cassano R, Ferrarelli T, Mauro MV, et al. (2014). Preparation, characterization and in vitro activities evaluation of solid lipid nanoparticles based on PEG-40 stearate for antifungal drugs vaginal delivery. Drug Deliv . [Epub ahead of print]. doi: 10.3109/10717544.2014.932862
   PubMed Web of Science ®Google Scholar
• Das R, Bhattacharya K, Samanta SK, et al. (2014). Improved chemosensitivity in cervical cancer to cisplatin: synergistic activity of mahanine through STAT3 inhibition. Cancer Lett 351:81–90
   PubMed Web of Science ®Google Scholar
• Diaz-Padilla I, Monk BJ, Mackay HJ, et al. (2013). Treatment of metastatic cervical cancer: future directions involving targeted agents. Crit Rev Oncol Hematol 85:303–14
   PubMed Web of Science ®Google Scholar
• Dixit N, Vaibhav K, Pandey RS, et al. (2015). Improved cisplatin delivery in cervical cancer cells by utilizing folate-grafted non-aggregated gelatin nanoparticles. Biomed Pharmacother 69:1–10
   PubMed Web of Science ®Google Scholar
• Gaba B, Fazil M, Ali A, et al. (2014). Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration. Drug Deliv . [Epub ahead of print]. doi: 10.3109/10717544.2014.898110
   PubMed Web of Science ®Google Scholar
• Han C, Li Y, Sun M, et al. (2014). Small peptide-modified nanostructured lipid carriers distribution and targeting to EGFR-overexpressing tumor in vivo. Artif Cells Nanomed Biotechnol 42:161–6
   PubMed Web of Science ®Google Scholar
• Han CY, Yue LL, Tai LY, et al. (2013). A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitro. Int J Nanomedicine 8:1541–9
   PubMed Web of Science ®Google Scholar
• He X, Li L, Su H, et al. (2015). Poly(ethylene glycol)-block-poly(ɛ-caprolactone) and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery. Int J Nanomedicine 10:1791–804
   PubMed Web of Science ®Google Scholar
• Iyer AK, Khaled G, Fang J, et al. (2006). Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 11:812–18
   PubMed Web of Science ®Google Scholar
• Jayant RD, McShane MJ, Srivastava R. (2009). Polyelectrolyte-coated alginate microspheres as drug delivery carriers for dexamethasone release. Drug Deliv 16:331–40
   PubMed Web of Science ®Google Scholar
• Jin W, Xu P, Zhan Y, et al. (2007). Degradable cisplatin-releasing core-shell nanogels from zwitterionic poly(beta-aminoester)-graft-PEG for cancer chemotherapy. Drug Deliv 14:279–86
   PubMed Web of Science ®Google Scholar
• Li Y, Wu H, Jia M, et al. (2014). Therapeutic effect of folate-targeted and PEGylated phytosomes loaded with a mitomycin C-soybean phosphatidyhlcholine complex. Mol Pharm 11:3017–26
   PubMed Web of Science ®Google Scholar
• Li YJ, Dong M, Kong FM, et al. (2015). Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics. Int J Pharm 489:83--90
   PubMed Web of Science ®Google Scholar
• Liu D, Liu F, Liu Z, et al. (2011). Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol Pharm 8:2291–301
   PubMed Web of Science ®Google Scholar
• Liu Q, Li J, Pu G, et al. (2015). Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy. Drug Deliv . [Epub ahead of print]. doi: 10.3109/10717544.2015.1031295
   Web of Science ®Google Scholar
• Maduro JH, Pras E, Willemse PH, et al. (2003). Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev 29:471–88
   PubMed Web of Science ®Google Scholar
• Negi LM, Talegaonkar S, Jaggi M, et al. (2014). Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part II. In vivo biodistribution, pharmacodynamic and hematological toxicity studies. Colloids Surf B Biointerfaces 123:610–15
   PubMed Web of Science ®Google Scholar
• Pandey V, Gajbhiye KR, Soni V. (2015). Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma. Drug Deliv 22:199–205
   PubMed Web of Science ®Google Scholar
• Rahman HS, Rasedee A, How CW, et al. (2013). Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect. Int J Nanomedicine 8:2769–81
   PubMed Web of Science ®Google Scholar
• Rostami E, Kashanian S, Azandaryani AH, et al. (2014). Drug targeting using solid lipid nanoparticles. Chem Phys Lipids 181:56–61
   PubMed Web of Science ®Google Scholar
• Skidan I, Miao B, Thekkedath RV, et al. (2009). In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL. Drug Deliv 16:45–51
   PubMed Web of Science ®Google Scholar
• Thukral DK, Dumoga S, Mishra AK. (2014). Solid lipid nanoparticles: promising therapeutic nanocarriers for drug delivery. Curr Drug Deliv 11:771–91
   PubMed Web of Science ®Google Scholar
• Torchilin VP. (2006). Multifunctional nanocarriers. Adv Drug Deliv Rev 58:1532–55
   PubMed Web of Science ®Google Scholar
• Torchilin VP. (2007). Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 9:E128–47
   PubMed Web of Science ®Google Scholar
• Tzioras S, Pavlidis N, Paraskevaidis E, et al. (2007). Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis. Cancer Treat Rev 33:24–38
   PubMed Web of Science ®Google Scholar
• Vhora I, Khatri N, Desai J, et al. (2014). Caprylate-conjugated cisplatin for the development of novel liposomal formulation. AAPS PharmSciTech 15:845–57
   PubMed Web of Science ®Google Scholar
• Xu X, Zhao C, Yang H, et al. (2009). Anti-inflammatory activity of injectable dexamethasone acetate-loaded nanostructured lipid carriers. Drug Deliv 18:485–92
   Web of Science ®Google Scholar
• Yokoyama M. (2005). Drug targeting with nano-sized carrier systems. J Artif Organs 8:77–84
   PubMedGoogle Scholar
• Zhang XG, Miao J, Dai YQ, et al. (2008). Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm 361:239–44
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang J. (2005). Surface modification of monodisperse magnetite nanoparticles for improved intracellular uptake to breast cancer cells. J Colloid Interface Sci 283:352–7
   PubMed Web of Science ®Google Scholar
• Zhao S, Zhang Y, Han Y, et al. (2015). Preparation and characterization of cisplatin magnetic solid lipid nanoparticles (MSLNs): effects of loading procedures of Fe3O4 nanoparticles. Pharm Res 32:482–91
   PubMed Web of Science ®Google Scholar
• Zhou X, Zhang X, Ye Y, et al. (2015). Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption. Int J Pharm 479:391–8
   PubMed Web of Science ®Google Scholar
• Zong S, Wang X, Yang Y, et al. (2015). The use of cisplatin-loaded mucoadhesive nanofibers for local chemotherapy of cervical cancers in mice. Eur J Pharm Biopharm 93:127--35
   PubMed Web of Science ®Google Scholar